Open Side Menu Go to the Top
Register
Covid-19 Discussion Covid-19 Discussion

02-26-2024 , 05:37 PM
I guess the article from BJ don’t understand that covid evolve many times during the pandemic and during June to October 2021 , what the art île makes allusion of , was exactly where the delays variant worlwide began to dominate .

Obviously the original vaccine for covid was still effective vs those variant but not has much .
So people still got sick but less then if they didn’t had vaccine at all .
Obv the link BJ quoted is hiding basic facts to have a bias view on vaccine ….

Ps: in other link made by the author so funny .
They use one week over 48 and say u see , vaccine not working because that 1 week only 3 patient without vaccine got sick while a lot more were needing to be at hospital .
No cherry picking at all lol .

Last edited by Montrealcorp; 02-26-2024 at 05:47 PM.
02-26-2024 , 05:54 PM
Quote:
Originally Posted by Brian James
Spoiler:
I'll take that as a no.
03-06-2024 , 11:08 AM
Well let's break the stony silence with some legitimate science.

This should be the final nail in the coffin of Ivermectin for COVID-19. Should be, but it should've been dead and buried long ago, of course.

Published about a week ago:
https://www.journalofinfection.com/a...064-1/fulltext

Findings

The primary analysis included 8811 SARS-CoV-2 positive participants (median symptom duration 5 days), randomised to ivermectin (n=2157), usual care (n=3256), and other treatments (n=3398) from June 23, 2021 to July 1, 2022. Time to self-reported recovery was shorter in the ivermectin group compared with usual care (hazard ratio 1·15 [95% Bayesian credible interval, 1·07 to 1·23], median decrease 2.06 days [1·00 to 3·06]), probability of meaningful effect (pre-specified hazard ratio ≥1.2) 0·192). COVID-19-related hospitalisations/deaths (odds ratio 1·02 [0·63 to 1·62]; estimated percentage difference 0% [-1% to 0·6%]), serious adverse events (three and five respectively), and the proportion feeling fully recovered were similar in both groups at 6 months (74·3% and 71·2% respectively (RR = 1·05, [1·02 to 1·08]) and also at 3 and 12 months.,.

Interpretation

Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.
03-06-2024 , 07:34 PM
Quote:
Originally Posted by Gorgonian
Well let's break the stony silence with some legitimate science.

This should be the final nail in the coffin of Ivermectin for COVID-19. Should be, but it should've been dead and buried long ago, of course.

Published about a week ago:
https://www.journalofinfection.com/a...064-1/fulltext

Findings

The primary analysis included 8811 SARS-CoV-2 positive participants (median symptom duration 5 days), randomised to ivermectin (n=2157), usual care (n=3256), and other treatments (n=3398) from June 23, 2021 to July 1, 2022. Time to self-reported recovery was shorter in the ivermectin group compared with usual care (hazard ratio 1·15 [95% Bayesian credible interval, 1·07 to 1·23], median decrease 2.06 days [1·00 to 3·06]), probability of meaningful effect (pre-specified hazard ratio ≥1.2) 0·192). COVID-19-related hospitalisations/deaths (odds ratio 1·02 [0·63 to 1·62]; estimated percentage difference 0% [-1% to 0·6%]), serious adverse events (three and five respectively), and the proportion feeling fully recovered were similar in both groups at 6 months (74·3% and 71·2% respectively (RR = 1·05, [1·02 to 1·08]) and also at 3 and 12 months.,.

Interpretation

Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.
As usual the first thing we check is the conflict of interest statement and unsurprisingly what do we find?

Quote:
Prof de Lusignan is Director of the Oxford-RCGP Research and Surveillance Centre and reports that through his University he has had grants outside the submitted work from AstraZeneca, GSK, Sanofi, Seqirus and Takeda for vaccine related research, and membership of advisory boards for AstraZeneca, Sanofi and Seqirus.
No need to read any further.
03-06-2024 , 08:00 PM
Quote:
Originally Posted by Brian James
As usual the first thing we check is the conflict of interest statement and unsurprisingly what do we find?



No need to read any further.
Nobody expected you to.

BTW, there are 25 authors on this paper. Every last one of them eminently qualified.

Your approval is not requested, required, nor even desired.
03-06-2024 , 11:58 PM
Quote:
Originally Posted by Gorgonian
Nobody expected you to.

BTW, there are 25 authors on this paper. Every last one of them eminently qualified.

Your approval is not requested, required, nor even desired.
Sorry buttercup but your Ivermectin study was fraudulent.

Approval is therefore denied.



Here is a comprehensive analysis of how and why it was fraudulent.

https://pierrekorymedicalmusings.com...ven-fraudulent

Also here.

https://worldcouncilforhealth.substa...dRedirect=true
03-07-2024 , 01:38 AM
Quote:
Originally Posted by Gorgonian
This should be the final nail in the coffin of Ivermectin for COVID-19. Should be, but it should've been dead and buried long ago, of course.

Published about a week ago:
https://www.journalofinfection.com/a...064-1/fulltext
The study suggests it reduced time to recovery by 2 days and most long covid symptoms across the board to a marginal but statistically significant degree. Hardly a nail in the coffin.

Quote:
Findings

[...]COVID-19-related hospitalisations/deaths (odds ratio 1·02 [0·63 to 1·62]; estimated percentage difference 0% [-1% to 0·6%]),
Do you know what sort of transformation is going on where hospitalization/death rates of 1.6% iver vs. 4.4% usual care becomes "estimated percentage difference 0%"?



Quote:
Interpretation

Ivermectin for COVID-19 is unlikely to provide clinically meaningful improvement in recovery, hospital admissions, or longer-term outcomes. Further trials of ivermectin for SARS-Cov-2 infection in vaccinated community populations appear unwarranted.
This is a bizarre interpretation/conclusion given the actual data.
03-07-2024 , 06:03 AM
We don't listen to Pierre Kory, sir.

You should probably read the Statistical Analysis section of the paper which explains that in great detail.

I suggest paying particularly attention to the parts discussing the futility rule.

"If there was insufficient evidence of a clinically meaningful benefit in time to recovery, futility was declared and randomisation to that intervention would be stopped, meaning other interventions could be evaluated more rapidly in the trial."

So simply looking at that pure recovery numbers which you did (because the grifter you got suckered by convinced you that's all that matters) is not enough to properly evaluate the effect.

The interesting part is that Pierre Kory is qualified enough to know this. One might wonder why he didn't pass this along.

Oh, he sells exorbitantly priced ivermectin treatments?

Well, that makes sense.

I went and looked at his supposed analysis, too. He's lies even more egregiously. He knows he can get away with it because the study design is complicated.

He claims the futility gate was fraudulent because it was designed to be used when ivermectin was showing no improvement in recovery time, but the results showed a 2 day improvement! Therefore lies!

Oh, silly, Pierre. The 2 day improvement result was after they switched to using treatments already known to improve outcomes because ivermectin wasn't working. You can't include those recovery times in the evaluation of whether they should have adjusted the treatments. Not honestly, anyway.

This is all included in the design of the study. He knows this because he's qualified. You can pay him exorbitant amounts of money for a hack ivermectin treatment package. This his constant crusade to demonstrate ivermectin is effective.

And people buy it. Literally and figuratively.

Go figure.

Last edited by Gorgonian; 03-07-2024 at 06:31 AM.
03-07-2024 , 07:57 AM
For clarity, here's the kind of thing I mean. The table referenced above (showing a 4.4 to 1.6 difference in severe outcomes) includes people who were not actually enrolled in the ivermectin arm of the study but were included in the dataset evaluating other treatments.

Focusing only on that result is nothing but pure dishonesty by Kory. The relevant results are quoted below.

Quote:
In the usual care group in concurrent randomisation analysis population, which excluded participants randomised to usual care before the ivermectin arm opened, there were 27/1806 (1.5%) COVID-19 related hospitalisations/deaths. In the Bayesian primary analysis model, which takes into account the temporal change in event rates, COVID-19 related hospitalisation/deaths in the ivermectin group compared to usual care were similar, with an estimated odds ratio of 1·017 (95% credible interval 0·633 to 1·622). Based on a bootstrap estimated hospitalization rate of 1·5% in the concurrent and eligible usual care population, the model-based estimated odds ratio corresponds to an estimated difference in the hospitalisation rate of 0% [ -1·0% to 0·6%]) (Table 2). The probability that COVID-19 related hospitalisations/deaths were lower in the ivermectin arm versus usual care (i.e. probability of superiority) was 0·472. The probability that there was a meaningful reduction in COVID-19 related hospitalisations/deaths (predefined as an odds ratio of 0·80 or smaller) was 0·223 which is below the 0·25 threshold indicating enrolment should stop for futility.

Last edited by Gorgonian; 03-07-2024 at 08:02 AM.
03-07-2024 , 08:16 AM
Another "error" Kory makes is conflating reduction in recovery time days to hazard ratio.

From the study:
"This result was statistically significant (HR = 1·14, 95% Interval= 1·07 – 1·23), but the estimated hazard ratio was less than the pre-specified meaningful effect of 1·2."

Kory claims that the study disagree swith itself since it predefined a relevant decrease in recovery time of 1.5 days or larger.

But it didn't.

Below is the pre definition statement:

For the purposes of defining futility rules, we pre-specified a clinically meaningful hazard ratio for time to first reported recovery as 1·2 or larger (equating to approximately 1·5 days difference in median time to recovery, assuming 9 days recovery in the usual care arm).

The key here is "assuming 9 days recovery in the usual care arm."

What was the median recovery in the usual care arm? 14. So no, the approximation of 1.5 for 9 days is not relevant here. The hazard ratio is all that actually applies and it was below the threshold (1.14 is less than 1.2).

Kory again misleads the reader. Shocked yet? There's still time to buy his ivermectin treatments!

edit to add: you can disregard my first reply, it was early and I confused some things. I retract that and stand by my most recent two.
03-07-2024 , 09:55 AM
lol

Further conflating the two figures (pure reduction in recovery days and hazard ratio) he then just blatantly lies and says:

"
to support this statement they instituted an almost impossible bar to clear, that of a “pre-specified hazard ratio level that must be greater than 2.0.”
"

Nowhere is a hazard ratio of 2.0 even mildly suggested. His 2 days of reduction equates, again, to a 1.14 hazard ratio (for the median 14 days of recovery in the control group). He either doesn't understand the difference between these numbers (he does, he's qualified) or he is blatantly lying

We can only guess why.

Edit: haha he even says it himself, but calls it "damning" (yeah, to his own argument):

"
Even more damning is that nowhere in their trial protocol is there any mention of setting an HR of 2.0 or greater as the requirement for “clinical meaningfulness.”
"

You don't say, eh doc? Then why did you just express incredulity at the fact that they did?

Hilarious.
03-07-2024 , 10:14 AM
More stupidity from this joke of a blog post.

"
So basically, they do not know how to randomize? Why even compare to a non-temporally related population? Who knows but they did, and when they did so, they found a massive reduction in mortality (from 4.4% down to 1.6%, a difference of 2.8%. My “question marks” in the above table refers to the fact that they instead report this difference as 0%. I have to admit I am lost on this one, and have no idea why this is.
"

Yes they know how to randomize. That's why the process was extensively documented in the paper. Including the reasons why you can't compare the non-temporally related populations. He acts baffled by this, but the reasons are obvious and explained in the paper.

And the paper doesn't compare the two. He does. They are listed in the paper, yes, for transparency, but the comparison is for the corrected groups from the same time period.

You obviously can't compare groups from different times. The control group initially contained tons of people from early in the pandemic when outcomes were much worse (lower immunity levels, lower care quality due to unknowns, triaging, etc.). The ivermectin group did not contain people from that period. That's why the rate was much higher.

When you remove that period and look at only the times when both groups were active, there was no reduction.

This seems simple and it's basic study design.

I pasted in the section of the study that details this in an earlier post.

Kory can't figure this out for some reason.

"I have to admit I am lost on this one, and have no idea why this is."

-Pierre Kory.

just lol
03-07-2024 , 07:04 PM
I looked briefly at some of the data and could possibly agree that there does seem to be some possible benefit for long covid, though the quality of that data is probably pretty low, which is likely why it's not really focused on in the meat of the paper. I'd need to spend more time examining the details of the data in that section to really comment further on it, but he isn't as egregiously wrong as he is on the rest of the paper on a quick glance about that part.
03-08-2024 , 12:54 PM
Here's another detailed summary of everything that is wrong with the study.

Quote:
Significantly improved recovery and significantly lower risk of long COVID with ivermectin, despite very late treatment, low-risk patients, and poor administration.

36% lower ongoing persistent COVID-19 specific symptoms, p<0.0001 (details below). The primary recovery outcome shows superiority of ivermectin (probability of superiority > 0.999), missing from the abstract (details below). The p values for sustained recovery, early sustained recovery, alleviation of all symptoms, and sustained alleviation are all < 0.0001.

The efficacy seen for ivermectin here is despite the trial being the most clearly designed to fail trial, with major bias in design, operation, analysis, and reporting. This trial is a great example of bias in clinical trials which will be covered in detail in the future.
https://c19ivm.org/principleivm.html
03-08-2024 , 02:39 PM
Oh look. A repeat of exactly the same crap I just debunked. Cool.

The very first graph just repeats the lie Kory spread about the reduction in hospitalization and death.

You know the one where he pretended to not understand why you can't compare different time periods? Remember that?

For some reason, whoever made this page doesn't get it either. Such an egregious mistake isn't what you want to lead off your website with.

I see this author also doesn't understand the HR issue either.

Yikes.

I also like how we're supposed to just not notice the 319% increase in ICU admissions for the ivermectin group in that same chart. Or the +151% ventilation rate.

So the summary is: no decrease in hospitalization or death, huge increase in ICU admissions and ventilations, but people said they felt better in 12 days instead of 14 on average.

And that's using the data from THAT website. Excepting of course the obvious incompetence of using an incorrect comparison for deaths and hospitaliatons, which I corrected.

Just shameless.

In case you think I may be exaggerating and don't want to click:



And they said using that graph to try to show ivermectin works

Last edited by Gorgonian; 03-08-2024 at 03:00 PM.
03-08-2024 , 03:10 PM
Lol

You haven't debunked anything. The study is a fraudulent bunch of crap which the link I posted outlines conclusively. It was designed and set up to fail.
03-08-2024 , 03:17 PM
mkay! Don't see why anyone would choose that 319% increase in ICU admissions that your website shows, or the 151% increase in ventilations that your website shows, but you do you!
03-08-2024 , 03:19 PM
03-08-2024 , 03:24 PM
Quote:
Originally Posted by Brian James
Weird! They accidentally left off ICU admissions and ventilations!

Here it is again. Maybe you can send them a note so they can update their graphic!



It's a good point, though. It's really important that those tiny improvements based on survey questions get reported and not the 300% increase in ICU admissions. ICU admissions are such a subjective measurement.

03-08-2024 , 03:25 PM
I know you're desperate to get something right dude but unfortunately you failed again just like your fraudulent study failed.

Once again my advice is take the L and move on.
03-08-2024 , 03:28 PM
lolololol

Keep trying, Brian.

Next person to post loses!

Last edited by Gorgonian; 03-08-2024 at 03:52 PM.
03-08-2024 , 03:46 PM
Good try dude but the verdict is still:

Spoiler:
Failed.
03-08-2024 , 04:20 PM
I mean the whole premise of the trial was fraudulent from the start.

Ivermectin is most effective when used as an early treatment, so what do they do? They run a trial using it as late treatment and go against all the recommendations for dosage, administration with food, duration etc. It was designed to fail on purpose in order to discredit IVM as a treatment.
03-08-2024 , 04:40 PM
Rigged!
03-08-2024 , 04:49 PM
Quote:
Originally Posted by Brian James
I mean the whole premise of the trial was fraudulent from the start.

Ivermectin is most effective when used as an early treatment, so what do they do? They run a trial using it as late treatment and go against all the recommendations for dosage, administration with food, duration etc. It was designed to fail on purpose in order to discredit IVM as a treatment.
If only they would've given it earlier it wouldn't have tripled the risk of ICU admission!

They should've used the dosage and scheduling recommended by all the tests that showed ivermectin works.

Oh wait.

      
m